{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T03:22:45Z","timestamp":1794540165940,"version":"4.9.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T00:00:00Z","timestamp":1758758400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["JYY2023-14"],"award-info":[{"award-number":["JYY2023-14"]}]},{"name":"Beijing Municipal Public Welfare Development and Reform Pilot Project for Medical Research Institutes","award":["JYY2023-15"],"award-info":[{"award-number":["JYY2023-15"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) bring significant clinical benefits to non-small-cell lung cancer (NSCLC), and convenient peripheral blood markers are still lacking. Human circulating cytokines play an important role in tumor growth and metastasis, and exploring their value in NSCLC immunotherapy helps to achieve precise treatment of patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This study was a mixed design of prospective blood collection and retrospective data collection. Patients with NSCLC who received the first ICI combined with chemotherapy were included, and plasma samples were collected at baseline and after 2 cycles of treatment. MILLIPLEX MAP technology was used to detect the levels of a panel of cancer biomarkers and to explore the predictive potential of cytokines for survival and treatment response in such patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Baseline blood samples were collected from 79 NSCLC patients in this study, and survival analysis showed that high expression of 4 cytokines, carbohydrate antigen 125 (CA125), cytokeratin 19 fragment (CYFRA 21-1), human epididymis protein 4 (HE4), and hepatocyte growth factor (HGF), was associated with shorter overall survival (OS) and progression-free survival (PFS), low levels of stem cell factor (SCF) tended to have better OS than patients with high levels of SCF, and multivariate Cox regression showed that high levels of HGF were independent risk factors for OS (HR\u2009=\u20091.92, 95% CI: 1.02-3.70, P\u2009=\u2009.042) and PFS (HR\u2009=\u20093.23, 95% CI: 1.75-5.88, P\u2009&amp;lt;\u2009.001). HGF was more predictive of 1-year survival and 6-month PFS than programmed death ligand 1 expression. In addition, we collected blood samples from 53 patients after 2 cycles of treatment, CYFRA 21-1, HGF, interleukin-8 (IL-8), and tumor necrosis factor-related apoptosis-inducing ligand were associated with patient survival, and patients with increased HGF after treatment had shorter survival. In patients whose tumors responded to treatment, CA125 and CYFRA 21-1 levels increased from baseline, whereas soluble apoptosis-related factor (sFas) levels decreased.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Soluble cytokines, especially HGF, have certain clinical value in immunotherapy combination therapy and prognosis of NSCLC patients and are worthy of validation in a larger prospective cohort and exploration of their potential mechanisms.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf306","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T13:54:48Z","timestamp":1758808488000},"source":"Crossref","is-referenced-by-count":3,"title":["A cohort study of circulating biomarkers to predict the efficacy and prognosis of immune combination therapy in non-small-cell lung cancer"],"prefix":"10.1093","volume":"30","author":[{"given":"Yanxia","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University , Beijing 100069,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6386-6640","authenticated-orcid":false,"given":"Xiaomi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Cancer Research Center, Beijing Tuberculosis and Thoracic Tumor Research Institute , Beijing 101149,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University , Beijing 100069,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University , Beijing 100069,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University , Beijing 100069,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaofa","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4271-3773","authenticated-orcid":false,"given":"Tongmei","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Oncology, Beijing Chest Hospital, Capital Medical University , Beijing 101149,","place":["China"]},{"name":"Laboratory for Clinical Medicine, Capital Medical University , Beijing 100069,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,25]]},"reference":[{"key":"2025101712310361000_oyaf306-B1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"2025101712310361000_oyaf306-B2","first-page":"216","article-title":"Etiology of lung cancer: evidence from epidemiologic studies","volume":"2","author":"Zou","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"2025101712310361000_oyaf306-B3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/S0025-6196(11)60735-0","article-title":"Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship","volume":"83","author":"Molina","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"2025101712310361000_oyaf306-B4","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1097\/JTO.0000000000000630","article-title":"The 2015 World Health Organization Classification of lung tumors: impact of genetic, clinical and radiologic advances since the 2004 classification","volume":"10","author":"Travis","year":"2015","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B5","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1200\/JCO.20.01605","article-title":"Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer","volume":"39","author":"Borghaei","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025101712310361000_oyaf306-B6","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1200\/JCO.21.00174","article-title":"Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score \u2265 50","volume":"39","author":"Reck","year":"2021","journal-title":"J Clin Oncol"},{"key":"2025101712310361000_oyaf306-B7","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.jtho.2021.05.001","article-title":"Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC","volume":"16","author":"Herbst","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B8","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101712310361000_oyaf306-B9","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N Engl J Med"},{"key":"2025101712310361000_oyaf306-B10","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.jtho.2021.07.015","article-title":"Updated overall survival data and predictive biomarkers of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"16","author":"Yang","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/1759-7714.12971","article-title":"Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"10","author":"Chen","year":"2019","journal-title":"Thorac Cancer"},{"key":"2025101712310361000_oyaf306-B12","doi-asserted-by":"crossref","DOI":"10.3390\/ph13110373","article-title":"First line immunotherapy for non-small cell lung cancer","volume":"13","author":"Nasser","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"2025101712310361000_oyaf306-B13","article-title":"Biomarkers for immunotherapy in driver-gene-negative advanced NSCLC","volume":"24","author":"Huang","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2025101712310361000_oyaf306-B14","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"2025101712310361000_oyaf306-B15","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1016\/j.jtho.2021.06.019","article-title":"Updated overall survival analysis from IMpower110: atezolizumab versus platinum-based chemotherapy in treatment-naive programmed death-ligand 1-selected NSCLC","volume":"16","author":"Jassem","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B16","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.jtho.2020.11.025","article-title":"Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial","volume":"16","author":"Nishio","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B17","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1200\/JCO.22.01989","article-title":"Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study","volume":"41","author":"Garassino","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025101712310361000_oyaf306-B18","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1111\/cas.14980","article-title":"Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan study","volume":"112","author":"Horinouchi","year":"2021","journal-title":"Cancer Sci"},{"key":"2025101712310361000_oyaf306-B19","doi-asserted-by":"crossref","first-page":"e2311181","DOI":"10.1001\/jamanetworkopen.2023.11181","article-title":"Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy","volume":"6","author":"Aggarwal","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2025101712310361000_oyaf306-B20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.3390\/ijms19051340","article-title":"Mechanisms of intrinsic tumor resistance to immunotherapy","volume":"19","author":"Rieth","year":"2018","journal-title":"Int J Mol Sci"},{"key":"2025101712310361000_oyaf306-B21","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.2147\/DDDT.S308578","article-title":"Clinical application of cytokines in cancer immunotherapy","volume":"15","author":"Qiu","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"2025101712310361000_oyaf306-B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41423-021-00786-6","article-title":"The use of supercytokines, immunocytokines, engager cytokines, and other synthetic cytokines in immunotherapy","volume":"19","author":"Zheng","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"2025101712310361000_oyaf306-B23","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1177\/1758834011422556","article-title":"An overview of the c-MET signaling pathway","volume":"3","author":"Organ","year":"2011","journal-title":"Ther Adv Med Oncol"},{"key":"2025101712310361000_oyaf306-B24","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1158\/1078-0432.CCR-06-0818","article-title":"Targeting the c-met signaling pathway in cancer","volume":"12","author":"Peruzzi","year":"2006","journal-title":"Clin Cancer Res"},{"key":"2025101712310361000_oyaf306-B25","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1158\/0008-5472.CAN-04-2650","article-title":"Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer","volume":"65","author":"Ma","year":"2005","journal-title":"Cancer Res"},{"key":"2025101712310361000_oyaf306-B26","doi-asserted-by":"crossref","first-page":"4579","DOI":"10.1158\/1078-0432.CCR-18-0267","article-title":"MET-oncogenic and JAK2-inactivating alterations are independent factors that affect regulation of PD-L1 expression in lung cancer","volume":"24","author":"Saigi","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2025101712310361000_oyaf306-B27","doi-asserted-by":"crossref","first-page":"13682","DOI":"10.18632\/oncotarget.24455","article-title":"Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer","volume":"9","author":"Albitar","year":"2018","journal-title":"Oncotarget"},{"key":"2025101712310361000_oyaf306-B28","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/s00262-024-03882-4","article-title":"Role of the HGF\/c-MET pathway in resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer","volume":"74","author":"Akli","year":"2025","journal-title":"Cancer Immunol Immunother"},{"key":"2025101712310361000_oyaf306-B29","doi-asserted-by":"crossref","first-page":"17588359231206282","DOI":"10.1177\/17588359231206282","article-title":"Dynamic monitoring of serum tumor markers as prognostic factors in patients with advanced non-small-cell lung cancer treated with first-line immunotherapy: a multicenter retrospective study","volume":"15","author":"Yang","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"2025101712310361000_oyaf306-B30","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2019.05.033","article-title":"Early serum tumor marker dynamics predict progression-free and overall survival in single PD-1\/PD-L1 inhibitor treated advanced NSCLC-A retrospective cohort study","volume":"134","author":"Lang","year":"2019","journal-title":"Lung Cancer"},{"key":"2025101712310361000_oyaf306-B31","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1186\/s12885-023-11312-4","article-title":"Baseline serum tumor markers predict the survival of patients with advanced non-small cell lung cancer receiving first-line immunotherapy: a multicenter retrospective study","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"2025101712310361000_oyaf306-B32","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s00432-024-05814-2","article-title":"Can blood-based markers predict RECIST progression in non-small cell lung cancer treated with immunotherapy?","volume":"150","author":"Yeghaian","year":"2024","journal-title":"J Cancer Res Clin Oncol"},{"key":"2025101712310361000_oyaf306-B33","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12967-019-1828-0","article-title":"The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to nivolumab in advanced non-small cell lung cancer (NSCLC) patients","volume":"17","author":"Dal Bello","year":"2019","journal-title":"J Transl Med"},{"key":"2025101712310361000_oyaf306-B34","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.lungcan.2019.02.017","article-title":"Potential for the blood-based biomarkers cytokeratin 19 fragment (CYFRA 21-1) and human epididymal protein 4 (HE4) to detect recurrence during monitoring after surgical resection of adenocarcinoma of the lung","volume":"130","author":"Muley","year":"2019","journal-title":"Lung Cancer"},{"key":"2025101712310361000_oyaf306-B35","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/s41420-019-0207-1","article-title":"Autoantibodies as diagnostic biomarkers for lung cancer: a systematic review","volume":"5","author":"Yang","year":"2019","journal-title":"Cell Death Discov"},{"key":"2025101712310361000_oyaf306-B36","doi-asserted-by":"crossref","first-page":"729","DOI":"10.4149\/neo_2022_220207N144","article-title":"New insights into the diagnostic characteristics and clinical application of serum biomarkers for lung cancer, and human epididymis protein 4 as a new biomarker?","volume":"69","author":"Li","year":"2022","journal-title":"Neoplasma"},{"key":"2025101712310361000_oyaf306-B37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/(SICI)1097-0215(19980119)75:2<171::AID-IJC1>3.0.CO;2-R","article-title":"Expression of the c-kit receptor and its ligand SCF in non-small-cell lung carcinomas","volume":"75","author":"Pietsch","year":"1998","journal-title":"Int J Cancer"},{"key":"2025101712310361000_oyaf306-B38","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/0190-9622(95)91274-6","article-title":"Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients","volume":"33","author":"Grichnik","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"2025101712310361000_oyaf306-B39","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1515\/CCLM.1999.141","article-title":"Stem cell factor and granulocyte-macrophage-colony stimulating factor as candidates for tumour markers for non-small-cell lung cancer","volume":"37","author":"Mroczko","year":"1999","journal-title":"Clin Chem Lab Med"},{"key":"2025101712310361000_oyaf306-B40","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/325265a0","article-title":"Tumour necrosis factor and lymphotoxin genes map close to H-2D in the mouse major histocompatibility complex","volume":"325","author":"M\u00fcller","year":"1987","journal-title":"Nature"},{"key":"2025101712310361000_oyaf306-B41","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s12672-024-00890-9","article-title":"TRAIL predisposes non-small cell lung cancer to ferroptosis by regulating ASK-1\/JNK1 pathway","volume":"15","author":"Liu","year":"2024","journal-title":"Discov Oncol"},{"key":"2025101712310361000_oyaf306-B42","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0b013e318217b6c8","article-title":"The tumor necrosis factor-related apoptosis-inducing ligand and lung cancer: still following the right TRAIL?","volume":"6","author":"McGrath","year":"2011","journal-title":"J Thorac Oncol"},{"key":"2025101712310361000_oyaf306-B43","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s13402-016-0278-4","article-title":"Schedule-dependent cytotoxicity of sunitinib and TRAIL in human non-small cell lung cancer cells with or without EGFR and KRAS mutations","volume":"39","author":"Bao","year":"2016","journal-title":"Cell Oncol (Dordr)"},{"key":"2025101712310361000_oyaf306-B44","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.molmed.2013.03.002","article-title":"CD95 in cancer: tool or target?","volume":"19","author":"Martin-Villalba","year":"2013","journal-title":"Trends Mol Med"},{"key":"2025101712310361000_oyaf306-B45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007310","article-title":"Increased interleukin-6\/C-reactive protein levels are associated with the upregulation of the adenosine pathway and serve as potential markers of therapeutic resistance to immune checkpoint inhibitor-based therapies in non-small cell lung cancer","volume":"11","author":"Naqash","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2025101712310361000_oyaf306-B46","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/1759-7714.14248","article-title":"Circulating cytokines associated with clinical outcomes in advanced non-small cell lung cancer patients who received chemoimmunotherapy","volume":"13","author":"Shi","year":"2022","journal-title":"Thorac Cancer"},{"key":"2025101712310361000_oyaf306-B47","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S1470-2045(12)70241-3","article-title":"Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials","volume":"13","author":"Tran","year":"2012","journal-title":"Lancet Oncol"},{"key":"2025101712310361000_oyaf306-B48","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1158\/1078-0432.CCR-22-1366","article-title":"Molecular mechanisms and future implications of VEGF\/VEGFR in cancer therapy","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025101712310361000_oyaf306-B49","doi-asserted-by":"crossref","first-page":"843250","DOI":"10.3389\/fonc.2022.843250","article-title":"Investigating the predictive value of vascular endothelial growth factor in the evaluation of treatment efficacy and prognosis for patients with non-surgical esophageal squamous cell carcinoma","volume":"12","author":"Kong","year":"2022","journal-title":"Front Oncol"},{"key":"2025101712310361000_oyaf306-B50","doi-asserted-by":"crossref","first-page":"841623","DOI":"10.3389\/fphar.2022.841623","article-title":"The strategies and mechanisms of immune checkpoint inhibitors for brain metastases in NSCLC","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"2025101712310361000_oyaf306-B51","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10092249","article-title":"Efficacy and safety of combined brain stereotactic radiotherapy and immune checkpoint inhibitors in non-small-cell lung cancer with brain metastases","volume":"10","author":"Porte","year":"2022","journal-title":"Biomedicines"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf306\/64394596\/oyaf306.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf306\/64394596\/oyaf306.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/10\/oyaf306\/64394596\/oyaf306.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T16:31:12Z","timestamp":1760718672000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf306\/8263833"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,25]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10,1]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf306","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,9,25]]},"article-number":"oyaf306"}}